is designed specifically to treat male pattern hair loss (androgenetic alopecia) in men. It’s effectiveness in bitemporal recession has not been proven, and it is not intended for use in women. This solution is to be applied topically to affected area only. The suggested usage is 1 ml applied to treatment area once daily. Generally, it takes at least three months of consistent use to see results, and ongoing use is necessary to maintain benefits. It is important to note that the topical application of finasteride is not as well studied as oral finasteride, and it is not currently FDA-approved. Topical finasteride has been shown to reduce both scalp and plasma DHT levels, and twice daily application of 0.25% finasteride solution has been shown to provide similar inhibition of plasma DHT as once-daily finasteride 1 mg oral tablet.1 Topical finasteride reduces the potential for systemic side effects, including the risk of sexual dysfunction. Periodic re-evaluation is advised. If treatment is discontinued, any positive effects will likely reverse within a year.
SIDE EFFECTS
As with any medication, some users may experience side effects. Topical application of finasteride decreases the chances of systemic effects compared to oral finasteride. Potential side effects include:
1. Side effects localized to the application site, including: scalp itchiness (pruritus), burning sensation, irritation, contact dermatitis, and erythema.
2. Decreased libido: Some users may experience a reduction in sexual desire.
3. Erectile dysfunction: Difficulty achieving or maintaining an erection may occur.
4. Ejaculation disorders: This may include decreased ejaculate volume or difficulty with ejaculation.
5. Testicular pain: Some men may experience pain or discomfort in the testicles.
6. Breast tenderness or enlargement: Changes in breast tissue, such as tenderness or swelling, may occur in some men.
7. Dizziness: Light-headedness or dizziness may occur, especially when standing up from a sitting or lying position.
8. Headaches: Some users may experience mild to moderate headaches.
9. Allergic reactions: These may include skin rash, itching, or hives, although these are less common.
10. Fatigue: Some users may experience increased tiredness or weakness.
11. Mood changes: This includes depression, anxiety, or other changes in mood, although these side effects are relatively rare.
It is important to note that not everyone will experience these side effects, and some people may experience no side effects at all. If you are concerned about any potential side effects, it is best to speak with your healthcare provider before starting or continuing the medication.
WARNINGS
1. Women's Exposure - Male Fetus Risk
Finasteride is not for women. Pregnant or potentially pregnant women should avoid handling the solution due to the risk of absorption and potential harm to a male fetus. Practice chemical safety when handling this prescription medication.
2. PSA Effects
In clinical studies with men aged 18 to 41, oral finasteride tablets reduced serum PSA levels. In older men with BPH, PSA levels decreased by about 50%. Finasteride may also lower PSA levels in prostate cancer patients. Consider these findings when interpreting PSA results for men on finasteride. Non-compliance may affect test results.
3. High-Grade Prostate Cancer Risk with 5-Reductase Inhibitors
Men aged 55+ in the 7-year PCPT with normal digital rectal exams and baseline PSA ≤3 ng/mL had an increased risk of high-grade prostate cancer when taking oral finasteride 5 mg/day. Similar results were found with dutasteride. The impact of 5α-reductase inhibitors on prostate volume or study-related factors is unclear.
4. Pediatric Patients
Finasteride is not for use in pediatric patients.
If you are experiencing a medical emergency, please call 911 or seek immediate medical attention.
You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This information is not comprehensive. Please visit dailymed.nlm.nih.gov for more information.
REFERENCE USED: 1https://pubmed.ncbi.nlm.nih.gov/35238144/#:~:tex